Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
As her kidneys fail and time runs short, this activist fights to decriminalize euthanasia in Mexico - 2The Advancement and Effect of Dental Embed Innovation on Oral Wellbeing
- 3Los Angeles County sees significant uptick in norovirus cases, officials say
- 4The most effective method to Pick the Best Material Organization: Insider Tips
- 5Saudi Arabia says it intercepted 7 missiles, debris falls near energy facilities
- The Way to Monetary Health: Individual budget Change
- Russia Fields New Ulan-2 All-Terrain Tactical Vehicle
- Figure out How to Explore Land Close to 5G Pinnacles
- To fix a patient's irregular heartbeat, doctors first tested its digital 'twin'
- Delta flight bound for Atlanta makes emergency landing after engine issue
- 10 Work Valuable chances to Assist with supporting Your Advanced degree
- Anthony Joshua's driver charged over Nigeria crash that killed two
- Chemical leak in Oklahoma forces evacuations and leaves many ill
- France's Senate backs ban on social media platforms for under-15s
